5 Best Stocks According to Clint Carlson’s Carlson Capital

3. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Carlson Capital’s Stake Value:  $74,312,000

Percentage of Carlson Capital’s 13F Portfolio: 5.1%

Number of Hedge Fund Holders: 58

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a clinical-stage biopharmaceutical business based in the United States, focuses on identifying and developing medicines for people suffering from severe neurological and neuropsychiatric illnesses. Clint Carlson’s Carlson Capital added Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to its Q2 2022 porfolio by obtaining 510,000 shares valued at $74.31 million, representing 5.1% of the total 13F portfolio.

Among the hedge funds tracked by Insider Monkey, 58 funds were bullish on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) at the end of June 2022, up from 41 funds in the prior quarter. Phill Gross And Robert Atchinson’s Adage Capital Management is the leading stakeholder of the company, with roughly 3.03 million shares worth $442 million.

Here is what Baron Health Care Fund has to say about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) in their Q1 2021 investor letter:

“Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology company dedicated to neurologic drug discovery. It launched its lead asset, migraine medication Nurtec, last year, and the company is transitioning towards profitability. Shares declined when Biohaven issued a secondary offering in March that took investors by surprise and seemed early in relation to an expected second indication for Nurtec in the prophylactic prevention of migraine, which expands its market. We exited our position.”